1. Use of a molecule comprising a payload linked to a gamma-carboxyglutamic acid component (GLA-component)
   wherein said GLA-component comprises a GLA domain or an active fragment thereof, and said molecule does not comprise an active catalytic domain from a GLA protein, in the manufacture of a medicament for targeting a stem cell.
2. Use according to claim 1, wherein the GLA domain or active fragment thereof is from thrombin, factor VII, factor IX, factor X, protein C, protein S, protein Z, osteocalcin, matrix GLA protein (MGP), GAS6, transthyretin (TTR), inter-alpha-trypsin-inhibitor, periostin, proline rich gla 1 (PRRG1), proline rich gla 2 (PRRG2), proline rich gla 3(PRRG3), or proline rich gla 4 (PRRG4).
3. Use according to claim 2, wherein the GLA domain or active fragment thereof is from protein S.
4. Use according to any one of claims 1 to 3, wherein the GLA-component further comprises an EGF domain, for example a calcium binding EGF domain.
5. Use according to any one of claims 1 to 4, wherein the construct comprises an EGF domain selected from thrombin, factor VII, factor IX, factor X, protein C, protein S, protein Z, Osteocalcin, Matrix GLA protein, GAS6, Transthretin, Periostin, Proline rich GLA 1, Proline rich GLA 2, Proline rich GLA 3 and Proline rich GLA 4.
6. Use according to claim 5 wherein the EGF domain is from protein S.
7. Use according to any of claims 1 to 6, wherein the GLA-domain component further comprises a Kringle domain.
8. Use according to claim 10, wherein the Kringle domain is from a protein selected from the group comprising Activating transcription factor 2 (ATF); Factor XII (F12); thrombin (F2); Hyaluronan-binding protein 2 (HABP2); Hepatocyte growth factor (HGF); Hepatocyte growth factor activator (HGFAC); Kremen protein 1 (KREMEN1); KREMEN2; Lipoprotein(a) (LPA); LPAL2; Macrophage-stimulating protein (MSP or MST1); Phosphoinositide-3-kinase-interacting protein 1 (PIK3IP1); Tissue plasminogen activator (PLAT); Urokinase (PLAU); Plasmin (PLG); PRSS12; Tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); and Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2).
9. Use according to any one of claims 1 to 8, wherein the GLA-component comprises a sequence shown in SEQ ID NO: 6.
10. Use according to any one of claims 1 to 9, wherein the method is performed *in vitro*.
11. Use according to any one of claims 1 to 9, wherein the delivery is to a cell *in vivo*, for example wherein the molecule comprising the GLA component and the payload are administered to a patient.
12. Use according to any one of claims 1 to 10, wherein the molecule targets the exterior of the stem cell.

13. Use according to any one of claims 1 to 11, wherein the molecule is internalised in the stem cell.
14. Use according to any one of claims 1 to 13, wherein the cell is non-apoptotic.
15. Use according to any one of claims 1 to 13, wherein the cell is apoptotic, for example a diseased stem cell.
16. Use according to any one of claims 1 to 14, wherein the stem cell is an embryonic stem cell or an adult stems cells including progenitor cells, and haemotopoietic stem cells, myogenic stem cells, osteoprogenitor stem cells, neural stem cells, mesenchymal stem cell, such as satellite cells, radial glial cells, bone marrow stromal cells, periosteum, pancreatic progenitor cells, endothelial progenitor cells, blast cells and trophoblast stem cells.
17. Use according to any one of claims 1 to 16, wherein the stem cell expresses a surface marker CD34.
18. Use according to any one of claims 1 to 17, wherein the stem cell is negative for lineage positive surface markers (i.e. is Lin -ve).
19. Use according to any one of claims 1 to 18, wherein the stem cell is CD90+ve, CD133+ve, CD105+ve, CD45+, Lin-ve, CD48-ve, and CD244-ve.
20. Use according to any one of claims 1 to 19, wherein the stem cell is Lin-ve, CD34+ve, CD38-ve, CD45RA-ve, CD90+ve and CD49f _+ve.
21. Use according to any one of claims 1 to 21, wherein the stem cell is non-cancerous.
22. Use according to any one of claims 1 to 22, wherein the stem cell is a cancer stem cell.
23. Use according to claim 23, wherein the cancer stem cell is of epithelial origin.
24. Use according to claim 22 or 23, wherein cancer stem cell expresses a surface marker selected from CD44 (which is over expressed in at least breast, ovary, prostate, pancreatic, squamous, and bladder cancer), CD133 (which is over expressed in at least brain, colon, lung, prostate cancer and medulloblastoma), CD24, CD90, CD271, CD4f, CD13 and combinations of two or more of the same.
25. Use according to any one of claims 1 to 22, wherein the stem cell is of haemotopoietic origin.